Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines
Purpose of review
Dyslipidaemia is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD) in type 2 diabetes. We provide an in-context overview of recent trials of lipid-lowering pharmacotherapies and of recommendations from international guidelines for managing dyslipidaemia in patients with diabetes.
Recent findings
Clinical trials have demonstrated that patients with diabetes derive greater benefits from ezetimibe and proprotein convertase subtilisin–kexin type 9 inhibitors owing to the higher absolute ASCVD risk compared with patients without diabetes. Pure eicosapentaenoic acid ethyl ester therapy should be considered in high risk patients with diabetes and hypertriglyceridaemia who have well controlled low-density lipoprotein cholesterol on statin therapy. International guidelines from USA, Canada and Europe have been updated to support a more intensive approach to treating dyslipidaemia in diabetes.
Summary
Dyslipidaemia should be identified and treated intensively as part of overall diabetes management to reduce ASCVD risk. Although lifestyle modifications and statin therapy remain the cornerstone of management, add-on therapies should be strongly considered depending on the absolute risk of ASCVD and the degree of dyslipidaemia.
Source: Current Opinion in Endocrinology, Diabetes and Obesity - Category: Endocrinology Tags: LIPIDS: Edited by Gerald F. Watts Source Type: research
More News: Canada Health | Cardiology | Cardiovascular | Cholesterol | Clinical Trials | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Obesity | Statin Therapy | Vytorin | Zetia